Tyrosine kinase inhibitors in patients with radioiodine-refractory, differentiated thyroid cancer Is there an optimal timepoint for their use?

Gundula Rendl; Gregor Schweighofer-Zwink; Christian Pirich

doi:10.1007/s41969-023-00185-4

Tyrosine kinase inhibitors in patients with radioiodine-refractory, differentiated thyroid cancer Is there an optimal timepoint for their use?

Gundula Rendl (Erstautor/-in), Gregor Schweighofer-Zwink (Co-Autor/-in), Christian Pirich^* (Letztautor/-in)

^*Korrespondierende/r Autor/-in für diese Arbeit

Universitätsklinikum für Nuklearmedizin und Endokrinologie

Publikation: Beitrag in Fachzeitschrift › Originalarbeit › Begutachtung

Originalsprache	Deutsch
Fachzeitschrift	AUSTRIAN JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM
DOIs	https://doi.org/10.1007/s41969-023-00185-4
Publikationsstatus	Veröffentlicht - 2023

Zugriff auf Dokument

10.1007/s41969-023-00185-4

Dieses zitieren

@article{9fdeceb4fe3547349a6df757a3e4a6ce,

title = "Tyrosine kinase inhibitors in patients with radioiodine-refractory, differentiated thyroid cancer Is there an optimal timepoint for their use?",

keywords = "THYROGLOBULIN DOUBLING-TIME, RADIOACTIVE IODINE, ASSOCIATION GUIDELINES, DOUBLE-BLIND, CARCINOMA, PAPILLARY, MANAGEMENT, SURVIVAL, PLACEBO",

author = "Gundula Rendl and Gregor Schweighofer-Zwink and Christian Pirich",

note = "Rendl, Schweighofer-Zwink, Pirich: Universit{\"a}tsklinik f{\"u}r Nuklearmedizin und Endokrinologie der PMU, Uniklinikum Salzburg, Salzburg, {\"O}sterreich",

year = "2023",

doi = "10.1007/s41969-023-00185-4",

language = "Deutsch",

journal = "AUSTRIAN JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM",

issn = "1998-7773",